Evgen Limited
Liverpool Science Park
Innovation Centre 2
146 Brownlow Hill
Liverpool L3 5RF
Tel: +44 (0) 151 705 3532
enquiries@evgen.com
Pioneering the clinical development of sulforaphane-based pharmaceuticals
Newsletters
June 2013
First-in-man trial on Sulforadex® completed: Prostate cancer trial to start in 2014
July 2012
The Promise of Sulforadex® in Cancer Therapy
February 2012
Evgen prepares for next investment round to advance Sulforadex® through Phase I trials
Press releases
10 December 2012
Sulforadex® enters First-in-Man Clinical Trial
5 July 2012
Evgen secures product development grant from UK's Technology Strategy Board
21 June 2012
Evgen retains Diagnostic Capital as corporate finance advisor
19 September 2011
Evgen set to develop pharmaceutical for patients with early stage prostate cancer
13 September 2011
Merseyside pharmaceutical firm secures Series A investment package
14 December 2010
University of Copenhagen awarded €1.8m grant to establish glucoraphanin fermentation technology
23 September 2010
Stabilised Sulforaphane Patent to be granted in United States
2 March 2010
Evgen and Kraft Foods enter into Option Agreement
4 February 2010
Evgen, PharmAgra Labs and Lalilab enter into Option Agreement
2 November 2009
Please direct all enquiries to enquiries@evgen.com
Company Registration Number : 06403643